Qiagen NV
QGEN48.290USD
-0.160-0.33%
Cierre 01/09, 16:00（ET）Cotizaciones retrasadas 15 min
10.45BCap. mercado
25.83P/E TTM
Más Datos de Qiagen NV Compañía
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Información de Qiagen NV
Símbolo de cotizaciónQGEN
Nombre de la empresaQiagen NV
Fecha de salida a bolsaSep 01, 1996
Director ejecutivoBernard (Thierry)
Número de empleados5765
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 01
DirecciónHulsterweg 82
CiudadVENLO
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísNetherlands
Código postal5912 PL
Teléfono31773556600
Sitio Webhttps://www.qiagen.com/
Símbolo de cotizaciónQGEN
Fecha de salida a bolsaSep 01, 1996
Director ejecutivoBernard (Thierry)
Ejecutivos de Qiagen NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+143556.00%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+134537.00%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-227680.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+4436.00%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+3835.00%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
+3973.00%
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
24.00
--
Dr. Toralf Haag, Ph.D.
Dr. Toralf Haag, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Eva Pisa, Ph.D.
Dr. Eva Pisa, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Bert van Meurs
Mr. Bert van Meurs
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+143556.00%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+134537.00%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-227680.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+4436.00%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+3835.00%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
+3973.00%
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables and Related Revenues
481.20M
90.35%
Instrumentation
51.38M
9.65%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
286.67M
53.83%
Europe & Middle East & Africa
172.58M
32.40%
Asia, Pacific & Rest of the World
73.33M
13.77%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables and Related Revenues
481.20M
90.35%
Instrumentation
51.38M
9.65%
Estadísticas de accionistas
Actualizado: lun., 17 de nov
Actualizado: lun., 17 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
Otro
68.78%
Accionistas
Accionistas
Proporción
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
Otro
68.78%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
48.66%
Investment Advisor
26.06%
Research Firm
5.08%
Pension Fund
1.63%
Sovereign Wealth Fund
1.60%
Hedge Fund
1.10%
Bank and Trust
1.09%
Individual Investor
0.44%
Insurance Company
0.07%
Otro
14.27%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
988
176.43M
85.64%
-25.04M
2025Q3
996
177.81M
82.00%
-32.33M
2025Q2
996
189.55M
87.53%
+6.64M
2025Q1
1017
179.03M
82.67%
+27.58M
2024Q4
1010
129.03M
59.70%
-70.06M
2024Q3
1010
183.22M
84.72%
-23.62M
2024Q2
1002
184.34M
84.75%
+8.40M
2024Q1
988
165.20M
76.61%
-7.18M
2023Q4
993
165.11M
76.72%
-10.52M
2023Q3
987
159.93M
74.32%
-12.21M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Wellington Management Company, LLP
23.33M
10.76%
-2.69M
-10.35%
Sep 30, 2025
MFS Investment Management
22.91M
10.56%
-570.88K
-2.43%
Sep 30, 2025
The Vanguard Group, Inc.
9.33M
4.3%
+169.45K
+1.85%
Sep 30, 2025
T. Rowe Price International Ltd
7.52M
3.47%
+1.59M
+26.73%
Sep 30, 2025
DWS Investment GmbH
4.62M
2.13%
+1.32M
+39.94%
Sep 30, 2025
EARNEST Partners, LLC
4.21M
1.94%
+6.14K
+0.15%
Sep 30, 2025
Amundi Asset Management, SAS
4.15M
1.91%
+170.89K
+4.30%
Sep 30, 2025
Boston Partners
4.02M
1.85%
+594.42K
+17.37%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.98M
1.84%
-16.38M
-80.43%
Sep 30, 2025
BofA Global Research (US)
3.61M
1.66%
+2.63M
+269.19%
Oct 21, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
First Trust Nasdaq Lux Digi Health Solutions ETF
4.04%
Global X Genomics & Biotechnology ETF
3.81%
Invesco Biotechnology & Genome ETF
2.54%
VanEck Biotech ETF
1.79%
ROBO Global Healthcare Technology & Innovation ETF
1.51%
Pacer US Large Cap Cash Cows Growth Leaders ETF
1.26%
iShares Health Innovation Active ETF
1.21%
First Trust Health Care Alphadex Fund
0.91%
Franklin Genomic Advancements ETF
0.86%
WisdomTree International Multifactor Fund
0.72%
Ver más
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción4.04%
Global X Genomics & Biotechnology ETF
Proporción3.81%
Invesco Biotechnology & Genome ETF
Proporción2.54%
VanEck Biotech ETF
Proporción1.79%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.51%
Pacer US Large Cap Cash Cows Growth Leaders ETF
Proporción1.26%
iShares Health Innovation Active ETF
Proporción1.21%
First Trust Health Care Alphadex Fund
Proporción0.91%
Franklin Genomic Advancements ETF
Proporción0.86%
WisdomTree International Multifactor Fund
Proporción0.72%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
May 07, 2025
QGEN.NB Final Cash Dividend of gross USD 0.25 paid on Jul 10, 2025 going ex on Jul 02, 2025
Jul 02, 2025
Jul 10, 2025
Jul 02, 2025
División de acciones
Fecha
Tipo
Relación
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Fecha
Tipo
Relación
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Qiagen NV?
Los cinco principales accionistas de Qiagen NV son:
Wellington Management Company, LLP posee 23.33M acciones, lo que representa el 10.76% del total de acciones.
MFS Investment Management posee 22.91M acciones, lo que representa el 10.56% del total de acciones.
The Vanguard Group, Inc. posee 9.33M acciones, lo que representa el 4.30% del total de acciones.
T. Rowe Price International Ltd posee 7.52M acciones, lo que representa el 3.47% del total de acciones.
DWS Investment GmbH posee 4.62M acciones, lo que representa el 2.13% del total de acciones.
Wellington Management Company, LLP posee 23.33M acciones, lo que representa el 10.76% del total de acciones.
MFS Investment Management posee 22.91M acciones, lo que representa el 10.56% del total de acciones.
The Vanguard Group, Inc. posee 9.33M acciones, lo que representa el 4.30% del total de acciones.
T. Rowe Price International Ltd posee 7.52M acciones, lo que representa el 3.47% del total de acciones.
DWS Investment GmbH posee 4.62M acciones, lo que representa el 2.13% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Qiagen NV?
Los tres principales tipos de accionista de Qiagen NV son:
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.
¿Cuántas instituciones poseen acciones de Qiagen NV (QGEN)?
A fecha de 2025Q4, 988 instituciones poseen acciones de Qiagen NV, con un valor de mercado combinado de aproximadamente 176.43M, lo que representa el 85.64% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en 3.64%.
¿Cuál es la mayor fuente de ganancias de Qiagen NV?
El FY2025Q3, el segmento empresarial Consumables and Related Revenues generó la ganancia más alta para Qiagen NV, ascendiendo a 481.20M y representando el 90.35% de la ganancia total.
